

DAC August 2025 meeting agenda
藥物建議委員會 2025 年 8 月會議議程 (只備英文版)
药物建议委员会 2025 年 8 月会议议程 (只备英文版)

Drugs/ indications: 藥物/ 適應症: 药物/ 适应症 Therapeutic Class: 治療組別: 治疗组别:

- | | |
|---|---|
| 1) Adalimumab (Hyrimoz) | Gastro-intestinal system/ Musculoskeletal & joint disease |
| 2) Amivantamab (Rybrevant) | Malignant disease and immunosuppression |
| 3) Apalutamide (Erleada) | Malignant disease and immunosuppression |
| 4) Asciminib (Scemblix) | Malignant disease and immunosuppression |
| 5) Atezolizumab (Tecentriq) | Malignant disease and immunosuppression |
| 6) Daratumumab /Lenalidomide (Darzalex/Revlimid) | Malignant disease and immunosuppression |
| 7) Dostarlimab (Jemperli) | Malignant disease and immunosuppression |
| 8) Dupilumab (Dupixent) | Respiratory system |
| 9) Durvalumab (Imfinzi) | Malignant disease and immunosuppression |
| 10) Eladocagene exuparvovec (Upstaza) | Nutrition and blood |
| 11) Elranatamab (Elrexio) | Malignant disease and immunosuppression |
| 12) Enzalutamide (Xtandi) | Malignant disease and immunosuppression |
| 13) Eravacycline (Xerava) | Infections |
| 14) Etanercept (Erelzi) | Musculoskeletal and joint disease / Skin |
| 15) Fenfluramine (Fintepla) | Central nervous system |
| 16) Gilteritinib (Xospata) | Malignant disease and immunosuppression |
| 17) Lenvatinib / Pembrolizumab (Lenvima/Keytruda) | Malignant disease and immunosuppression |
| 18) Maralixibat (Livmarli) | Gastro-intestinal system |
| 19) Nirsevimab (Beyfortus) | Infections |
| 20) Nivolumab (Opdivo) | Malignant disease and immunosuppression |
| 21) Nivolumab / Ipilimumab (Opdivo / Yervoy) | Malignant disease and immunosuppression |
| 22) Olaparib (Lynparza) | Malignant disease and immunosuppression |
| 23) Ravulizumab (Ultomiris) | Nutrition and blood |
| 24) Roxadustat (Evrenzo) | Nutrition and blood |
| 25) Ruriectocog alfa pegol (Adynovate) | Cardiovascular system |
| 26) Secukinumab (Cosentyx) | Musculoskeletal and joint disease |
| 27) Solriamfetol (Sunosi) | Central nervous system |
| 28) Spesolimab (Spevigo) | Skin |
| 29) Tazemetostat (Tazverik) | Malignant disease and immunosuppression |
| 30) Tirzepatide (Mounjaro) | Endocrine system |
| 31) Tislelizumab (Tevimbra) | Malignant disease and immunosuppression |
| 32) Toripalimab (Loqtorzi) | Malignant disease and immunosuppression |
| 33) Ustekinumab (Wezlana) | Musculoskeletal and joint disease / Skin |
| 34) Venetoclax (Vencloxta) | Malignant disease and immunosuppression |
| 35) Vutrisiran (Amvuttra) | Central nervous system |
| 36) Zanubrutinib (Brukinsa) | Malignant disease and immunosuppression |